I. Robert-bobée, Projections de population pour la france métropolitaine à l'horizon 2050: INSEE 2006 Contract No.: n°1089. 2. World population ageing, United Nations, 2002.

C. Cottart, C. Laguillier, V. Nivet-antoine, C. Klimczak, C. Sebban et al., Biologie du vieillissement art??riel et art??rioscl??rose, Comptes Rendus Biologies, vol.332, issue.5, pp.433-480, 2009.
DOI : 10.1016/j.crvi.2008.10.002

A. Benetos, Acc??l??rateurs du??vieillissement art??riel, La Revue de M??decine Interne, vol.27, issue.2, pp.44-49, 2006.
DOI : 10.1016/j.revmed.2006.03.024

A. Benetos, C. Adamopoulos, J. Bureau, M. Temmar, C. Labat et al., Determinants of accelerated progression of arterial stiffness in normotensive subjects and in treated hypertensive subjects over a 6-year period. Circulation, pp.1202-1209, 2002.

A. Aviv, D. Levy, and M. Mangel, Growth, telomere dynamics and successful and unsuccessful human aging, Mechanisms of Ageing and Development, vol.124, issue.7, pp.829-866, 2003.
DOI : 10.1016/S0047-6374(03)00143-X

R. Cawthon, K. Smith, O. Brien, E. Sivatchenko, A. Kerber et al., Association between telomere length in blood and mortality in people aged 60 years or older, The Lancet, vol.361, issue.9355, pp.393-398, 2003.
DOI : 10.1016/S0140-6736(03)12384-7

M. Mcqueen, S. Hawken, X. Wang, S. Ounpuu, A. Sniderman et al., Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study, The Lancet, vol.372, issue.9634, pp.224-257, 2008.
DOI : 10.1016/S0140-6736(08)61076-4

P. Libby, G. Sukhova, R. Lee, and Z. Galis, Cytokines Regulate Vascular Functions Related to Stability of the Atherosclerotic Plaque, Journal of Cardiovascular Pharmacology, vol.25, issue.2, pp.9-12, 1995.
DOI : 10.1097/00005344-199500252-00003

R. Ross, Atherosclerosis--an inflammatory disease. The New England journal of medicine, pp.115-141, 1999.

S. Kritchevsky, M. Cesari, and M. Pahor, Inflammatory markers and cardiovascular health in older adults. Cardiovascular research, pp.265-75, 2005.

J. Stamler, D. Wentworth, and J. Neaton, Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT), JAMA: The Journal of the American Medical Association, vol.256, issue.20, pp.2823-2831, 1986.
DOI : 10.1001/jama.256.20.2823

C. Baigent, A. Keech, P. Kearney, L. Blackwell, G. Buck et al., Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet, pp.1267-78, 2005.

P. Delahoy, D. Magliano, K. Webb, M. Grobler, and D. Liew, The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: An updated meta-analysis, Clinical Therapeutics, vol.31, issue.2, pp.236-280, 2009.
DOI : 10.1016/j.clinthera.2009.02.017

D. Gordon, J. Probstfield, R. Garrison, J. Neaton, W. Castelli et al., High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation, pp.8-15, 1989.

E. Niesor, Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism, Current Opinion in Lipidology, vol.22, issue.4, pp.288-95, 2011.
DOI : 10.1097/MOL.0b013e3283475e00

D. Angelantonio, E. Sarwar, N. Perry, P. Kaptoge, S. Ray et al., Major lipids, apolipoproteins, and risk of vascular disease, Jama, vol.302, 1993.

S. Abourbih, K. Filion, L. Joseph, E. Schiffrin, S. Rinfret et al., Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial, Am J Med. Lancet, vol.122366, pp.1849-61, 2005.

N. Sarwar, M. Sandhu, S. Ricketts, A. Butterworth, D. Angelantonio et al., Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet, pp.1634-1643, 2010.

P. Ducimetière, Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Arteriosclerosis, thrombosis, and vascular biology, pp.1155-61, 2002.

S. Marcovina, J. Albers, F. Dati, T. Ledue, and R. Ritchie, International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B, Clin Chem, vol.37, pp.1676-82, 1991.

M. Benn, B. Nordestgaard, G. Jensen, and A. Tybjaerg-hansen, Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study. Arteriosclerosis, thrombosis, and vascular biology, 2007.

T. Pischon, C. Girman, F. Sacks, N. Rifai, M. Stampfer et al., Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk, Ann Intern Med, vol.112146, issue.27, pp.3375-83640, 2005.

P. Ridker, N. Rifai, N. Cook, G. Bradwin, and J. Buring, Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III), Jama. Jama, vol.294285, issue.29, pp.326-332486, 2001.

J. Robinson, S. Wang, B. Smith, and T. Jacobson, Meta-Analysis of the Relationship Between Non???High-Density Lipoprotein Cholesterol Reduction and Coronary Heart Disease Risk, Journal of the American College of Cardiology, vol.53, issue.4, pp.316-338, 2009.
DOI : 10.1016/j.jacc.2008.10.024

G. Luc, J. Bard, I. Juhan-vague, J. Ferrieres, A. Evans et al., C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study. Arteriosclerosis, thrombosis, and vascular biology, pp.1255-61, 2003.

J. Pai, T. Pischon, J. Ma, J. Manson, S. Hankinson et al., Inflammatory Markers and the Risk of Coronary Heart Disease in Men and Women, New England Journal of Medicine, vol.351, issue.25, pp.2599-610, 2004.
DOI : 10.1056/NEJMoa040967

P. Ridker, N. Rifai, L. Rose, J. Buring, and N. Cook, Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events

J. Danesh, J. Wheeler, G. Hirschfield, S. Eda, G. Eiriksdottir et al., C-Reactive Protein and Other Circulating Markers of Inflammation in the Prediction of Coronary Heart Disease, New England Journal of Medicine, vol.350, issue.14, pp.1387-97, 2004.
DOI : 10.1056/NEJMoa032804

T. Pearson, G. Mensah, R. Alexander, J. Anderson, R. Cannon et al., Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the, Centers for Disease Control and Prevention and the American Heart Association. Circulation, vol.107, pp.499-511, 2003.

F. Wensley, P. Gao, S. Burgess, S. Kaptoge, D. Angelantonio et al., Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data Archives of internal medicine, BMJ, vol.342153, pp.1065-73, 1993.

T. Manolio, T. Pearson, N. Wenger, E. Barrett-connor, G. Payne et al., Cholesterol and heart disease in older persons and women. Review of an NHLBI workshop. Annals of epidemiology, pp.161-76, 1992.

J. Robbins, G. Burke, A. Newman, and C. Furberg, The association between lipid levels and the risks of incident myocardial infarction, stroke, and total mortality: The Cardiovascular Health Study, J Am Geriatr Soc, vol.52, pp.1639-1686, 2004.

R. Clarke, J. Emberson, S. Parish, A. Palmer, M. Shipley et al., Cholesterol fractions and apolipoproteins as risk factors for heart disease mortality in older men Arch Intern Med, Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial, pp.1373-1381, 2002.

M. Cesari, B. Penninx, A. Newman, S. Kritchevsky, B. Nicklas et al., Inflammatory markers and onset of cardiovascular events, ACC Current Journal Review, vol.13, issue.2, pp.2317-2339, 2003.
DOI : 10.1016/j.accreview.2003.12.005

R. Tracy, A. Pradhan, J. Manson, J. Rossouw, D. Siscovick et al., C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study. Circulation Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study, Jama, vol.112288, issue.46, pp.25-31980, 2002.

L. Kuller, Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arteriosclerosis, thrombosis, and vascular biology, pp.1121-1128, 1997.

I. Tzoulaki, G. Murray, A. Lee, A. Rumley, G. Lowe et al., Relative Value of Inflammatory, Hemostatic, and Rheological Factors for Incident Myocardial Infarction and Stroke: The Edinburgh Artery Study, Circulation, vol.115, issue.16, pp.2119-2146, 2007.
DOI : 10.1161/CIRCULATIONAHA.106.635029

L. Kuller, L. Shemanski, B. Psaty, N. Borhani, J. Gardin et al., Subclinical disease as an independent risk factor for cardiovascular disease. Circulation, 51. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation, pp.720-63143, 1995.

N. Zakai, R. Katz, N. Jenny, B. Psaty, A. Reiner et al., Inflammation and hemostasis biomarkers and cardiovascular risk in the elderly: the Cardiovascular Health Study, Journal of Thrombosis and Haemostasis, vol.342, issue.6, pp.1128-1163, 2007.
DOI : 10.1111/j.1538-7836.2007.02528.x

W. De-ruijter, R. Westendorp, W. Assendelft, W. Den-elzen, A. De-craen et al., Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study, BMJ, vol.338, issue.jan08 2, p.3083, 2009.
DOI : 10.1136/bmj.a3083

E. Ingelsson, E. Schaefer, J. Contois, J. Mcnamara, L. Sullivan et al., Clinical Utility of Different Lipid Measures for Prediction of Coronary Heart Disease in Men and Women, JAMA, vol.298, issue.7, pp.776-85, 2007.
DOI : 10.1001/jama.298.7.776

N. Cook, Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation, Feb, vol.20115, pp.928-963, 2007.

M. Pencina, D. Agostino, R. Sr, R. Agostino, J. Vasan et al., Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond157-72; discussion 207-12. 57. Vascular factors and risk of dementia: design of the Three-City Study and baseline characteristics of the study population, Neuroepidemiology, vol.2722, pp.316-341, 2003.

C. Dufouil, F. Richard, N. Fievet, J. Dartigues, K. Ritchie et al., APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: The Three-City Study, Neurology, vol.64, issue.9, pp.1531-1539, 2005.
DOI : 10.1212/01.WNL.0000160114.42643.31
URL : https://hal.archives-ouvertes.fr/inserm-00175952

J. Empana, M. Zureik, J. Gariepy, D. Courbon, J. Dartigues et al., The metabolic syndrome and the carotid artery structure in noninstitutionalized elderly subjects: the three-city study. Stroke L'étude des Trois cités : relation entre pathologie vasculaire et démence, Rev Med Ass Maladie, vol.3837, issue.60, pp.893-9117, 2006.

R. Prentice, W. Barlow, L. Ichikawa, D. Rosner, and S. Izumi, A case-cohort design for epidemiologic cohort studies and disease prevention trials Analysis of case-cohort designs, Biometrika. J Clin Epidemiol, vol.7352, issue.62, pp.1-111165, 1986.

A. Thiebaut and J. Benichou, Choice of time-scale in Cox's model analysis of epidemiologic cohort data: a simulation study, Statistics in Medicine, vol.6, issue.2, pp.3803-3823, 2004.
DOI : 10.1002/sim.2098

F. Harrell, J. Lee, K. Mark, and D. , MULTIVARIABLE PROGNOSTIC MODELS: ISSUES IN DEVELOPING MODELS, EVALUATING ASSUMPTIONS AND ADEQUACY, AND MEASURING AND REDUCING ERRORS, Statistics in Medicine, vol.15, issue.4, pp.361-87, 1996.
DOI : 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4

H. Marti and M. Chavance, Multiple imputation analysis of case-cohort studies, Statistics in Medicine, vol.366, issue.13, pp.1595-607, 2011.
DOI : 10.1002/sim.4130
URL : https://hal.archives-ouvertes.fr/hal-00564016

A. Alperovitch, . Ap, J. Dartigues, P. Ducimetière, B. Mazoyer et al., Les ??tudes ??pid??miologiques sur le vieillissement en France??: de l?????tude Paquid ?? l?????tude des Trois Cit??s, Comptes Rendus Biologies, vol.325, issue.6, pp.665-72, 2002.
DOI : 10.1016/S1631-0691(02)01476-2

S. Kulathinal, J. Karvanen, O. Saarela, and K. Kuulasmaa, Case-cohort design in practice ??? experiences from the MORGAM Project, Epidemiologic Perspectives & Innovations, vol.4, issue.1, pp.15-69, 2007.
DOI : 10.1093/biomet/87.1.49

P. Ridker, Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT), Journal of Thrombosis and Haemostasis, vol.28, issue.Suppl. 1, 2009.
DOI : 10.1111/j.1538-7836.2009.03404.x

N. Rodondi, P. Marques-vidal, J. Butler, K. Sutton-tyrrell, J. Cornuz et al., Markers of Atherosclerosis and Inflammation for Prediction of Coronary Heart Disease in Older Adults, American Journal of Epidemiology, vol.171, issue.5, pp.540-549, 2010.
DOI : 10.1093/aje/kwp428

P. Ridker, E. Danielson, F. Fonseca, J. Genest, A. Gotto et al., Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C- Reactive Protein, pp.2195-207, 2008.

E. Spatz, M. Canavan, and M. Desai, From Here to JUPITER: Identifying New Patients for Statin Therapy Using Data From the 1999-2004 National Health and Nutrition Examination Survey, Circulation: Cardiovascular Quality and Outcomes, vol.2, issue.1, pp.41-49, 2009.
DOI : 10.1161/CIRCOUTCOMES.108.832592

S. Badola, B. Astor, A. Hofman, A. Pouta, K. Werdan et al., Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels, Circulation Feb, vol.22123, pp.731-739, 2011.

M. Kivimaki, D. Lawlor, G. Smith, M. Kumari, A. Donald et al., Does High C-reactive Protein Concentration Increase Atherosclerosis? The Whitehall II Study, PLoS ONE, vol.90, issue.8, p.3013, 2008.
DOI : 10.1371/journal.pone.0003013.t005

D. Nondahl, B. Klein, P. Mcbride, M. Sager, C. Schubert et al., Association of polymorphisms in the CRP gene with circulating C-reactive protein levels and cardiovascular events Increased atherogenic lipoproteins are associated with cognitive impairment: effects of statins and subclinical atherosclerosis, Jama. Alzheimer Dis Assoc Disord, vol.29623, pp.2703-1111, 2006.

J. Arnaud, T. Akbaraly, I. Hininger-favier, C. Berr, and A. Roussel, Fibrates but not statins increase plasma selenium in dyslipidemic aged patients ??? The EVA study, Journal of Trace Elements in Medicine and Biology, vol.23, issue.1, pp.21-29, 2009.
DOI : 10.1016/j.jtemb.2008.08.001
URL : https://hal.archives-ouvertes.fr/inserm-00319551

P. Ridker, J. Genest, S. Boekholdt, P. Libby, A. Gotto et al., HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial, The Lancet, vol.376, issue.9738, pp.333-342, 2010.
DOI : 10.1016/S0140-6736(10)60713-1

M. Clearfield, J. Downs, S. Weis, E. Whitney, W. Kruyer et al., Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): Efficacy and Tolerability of Long-Term Treatment with Lovastatin in Women, Journal of Women's Health & Gender-Based Medicine, vol.10, issue.10, pp.971-81, 2001.
DOI : 10.1089/152460901317193549

C. Jackevicius, M. Mamdani, and J. Tu, Adherence With Statin Therapy in Elderly Patients With and Without Acute Coronary Syndromes, JAMA, vol.288, issue.4, pp.462-469, 2002.
DOI : 10.1001/jama.288.4.462

D. Voora, S. Shah, I. Spasojevic, S. Ali, C. Reed et al., The SLCO1B1*5 genetic variant is associated with statin-induced side effects Journal of the American College of Cardiology Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) Circulation, Gotto AM Feb, vol.54101, issue.8, pp.1609-16477, 2000.

R. Simes, I. Marschner, D. Hunt, D. Colquhoun, D. Sullivan et al., Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by onstudy lipid levels? Circulation, pp.1162-1171, 2002.

J. Kastelein, W. Van-der-steeg, I. Holme, M. Gaffney, N. Cater et al., Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation, pp.3002-3011, 2008.

C. Packard, I. Ford, M. Robertson, J. Shepherd, G. Blauw et al., Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation, pp.3058-65, 2005.

P. Deedwania, P. Stone, B. Merz, C. Cosin-aguilar, J. Koylan et al., Effects of Intensive Versus Moderate Lipid-Lowering Therapy on Myocardial Ischemia in Older Patients With Coronary Heart Disease: Results of the Study Assessing Goals in the Elderly (SAGE), Circulation, vol.115, issue.6, pp.700-707, 2007.
DOI : 10.1161/CIRCULATIONAHA.106.654756

R. Glynn, W. Koenig, B. Nordestgaard, J. Shepherd, P. Ridker et al., Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average lowdensity lipoprotein cholesterol levels: exploratory analysis of a randomized trial Statin therapy and the elderly: SAGE advice? Circulation, W174. 91. Gotto AM, pp.488-96681, 2007.

J. Arnlov, Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. The New England journal of medicine, pp.2107-2123, 2008.

S. Blankenberg, T. Zeller, O. Saarela, A. Havulinna, F. Kee et al., Contribution of 30 Biomarkers to 10-Year Cardiovascular Risk Estimation in 2 Population Cohorts: The MONICA, Risk, Genetics, Archiving, and Monograph (MORGAM) Biomarker Project, Circulation, vol.121, issue.22, pp.2388-97, 2010.
DOI : 10.1161/CIRCULATIONAHA.109.901413